Enzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer
WEDNESDAY, Oct. 18, 2023 -- For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published in the Oct. 19 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?
(MedPage Today) -- Come December, as I observe my "pros-mitzvah" -- 13 years on active surveillance (AS) for very low-risk prostate cancer -- I feel I'm at a tipping point.
Should I stay the course and keep monitoring my lesion -- a single... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 18, 2023 Category: Hematology Source Type: news
Hope for thousands of men battling prostate cancer as scientists discover 'practice changing' drug combination that slashes risk of disease returning by 60%
Patients with prostate cancer who were given enzalutamide alongside the standard hormone treatment cut their chances of dying by 58 per cent, found researchers based in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - October 18, 2023 Category: Consumer Health News Source Type: news
How AI Can Make Cancer Treatment More Equitable
Many are aware of the Cancer Moonshot—an ambitious and hopeful initiative of the U.S. government to reduce cancer-related death rates by 50% by the year 2047. It will take an army to achieve this goal, composed of the brightest minds and biggest hearts in healthcare, science, and technology. Many parties will be involved—the federal government, healthcare providers, researchers, patients, caregivers, and advocates, among others in both the public and private sectors. One of the most pivotal tools that can help propel us toward this lofty goal is artificial intelligence (AI), which is poised to revolutionize can...
Source: TIME: Health - October 18, 2023 Category: Consumer Health News Authors: Andre Esteva Tags: Uncategorized Innovation Source Type: news
J & J ’s Medical Device Sales Feel the Side Effects of Weight-Loss Drugs
Riding high, Johnson & Johnson reported pharmaceutical sales worth $13.89 billion on Tuesday (Oct 17), a year-over-year growth exceeding 5%. The pharmaceuticals driving its growth are Darzalex, a biologic used for multiple myeloma, and Erleada, a prostate cancer treatment, in addition to several…#johnsonjohnson #darzalex #erleada #imbruvica #abiomed #altopharmacy #teamcubancard #medtechdivision #obese #glp1 (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2023 Category: Consumer Health News Source Type: news
